Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms
Authors
Keywords
-
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 21, Issue 12, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-08
DOI
10.1007/s11864-020-00794-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).
- (2020) Arvind Dasari et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).
- (2019) Jaume Capdevila et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).
- (2019) Emily K. Bergsland et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA76Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)
- (2019) J Xu et al. ANNALS OF ONCOLOGY
- The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia
- (2018) Frediano Inzani et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018
- (2018) Manisha H. Shah et al. Journal of the National Comprehensive Cancer Network
- Multicenter phase 2 study of nintedanib in patients (pts) with advanced progressing carcinoid tumors.
- (2018) Renuka V. Iyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).
- (2017) Jennifer A. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.
- (2017) Eric Raymond et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518
- (2017) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Marianne E Pavel et al. LANCET ONCOLOGY
- Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
- (2017) Piero Ferolla et al. LANCET ONCOLOGY
- Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial
- (2017) Hope S Rugo et al. LANCET ONCOLOGY
- Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
- (2017) Jian Ming Xu et al. Oncotarget
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- (2017) Arvind Dasari et al. JAMA Oncology
- Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study
- (2016) Namrata Vijayvergia et al. BRITISH JOURNAL OF CANCER
- A phase II study of axitinib in advanced neuroendocrine tumors
- (2016) J R Strosberg et al. ENDOCRINE-RELATED CANCER
- Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis
- (2016) Omar Abdel-Rahman et al. Future Oncology
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
- (2016) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors
- (2016) Geoffrey Wayne Krampitz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling
- (2016) Elizabeth Allen et al. Cell Reports
- Everolimus in the management of metastatic neuroendocrine tumours
- (2016) David L. Chan et al. Therapeutic Advances in Gastroenterology
- Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
- (2015) E. Grande et al. ANNALS OF ONCOLOGY
- Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model
- (2015) R. Bill et al. CLINICAL CANCER RESEARCH
- Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study
- (2015) Alexandria T Phan et al. LANCET ONCOLOGY
- Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for ‘Off-Target' Effects Not Mediated by c-Met Inhibition
- (2015) Clemens Reuther et al. NEUROENDOCRINOLOGY
- Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors
- (2014) Jennifer Chan et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
- (2013) Jennifer A. Chan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice
- (2013) B. Sennino et al. CANCER RESEARCH
- Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)
- (2013) Daniel Castellano et al. EUROPEAN JOURNAL OF CANCER
- Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors
- (2013) Zhi Rong Qian et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine Tumors
- (2012) Judith A. Gilbert et al. PANCREAS
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
- (2011) Ben Lawrence et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
- (2011) Y. Jiao et al. SCIENCE
- VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis
- (2010) Scott R. Silva et al. INTERNATIONAL JOURNAL OF CANCER
- The Pathologic Classification of Neuroendocrine Tumors
- (2010) David S. Klimstra et al. PANCREAS
- An Analysis of Trends and Growth Factor Receptor Expression of GI Carcinoid Tumors
- (2009) Kanika A. Bowen et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)
- (2009) Gerald J. Roth et al. JOURNAL OF MEDICINAL CHEMISTRY
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- (2008) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search